Full-Time

Associate Director Regional Contracts Lead

Posted on 9/16/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

No salary listed

Remote in Australia

Remote

Category
Legal & Compliance (2)
,
Required Skills
JIRA
Google Cloud Platform
Requirements
  • Bachelor’s degree; JD highly preferred or 8+ years of outstanding experience managing and negotiating clinical trial agreements and budgets
  • Experience in the CRO or pharmaceutical industry is essential
  • Good knowledge of ICH-Good Clinical Practice, pharmaceutical related regulations and laws
  • Good understanding of clinical trial contracting process, and relevant clinical operation practices
  • Awareness and understanding of compliance and regulatory matters in clinical research
  • Proven negotiation, interpersonal and business skills
  • Strong planning and organizational skills and the ability to work independently and effectively in a dynamic environment with competing priorities
  • Sense of urgency and strong goal orientation; track-record of meeting deadlines and goals
  • Strong written and verbal communication including written and verbal fluency in English and local language (if not English) and interpersonal skills, including conflict resolution and problem solving
  • Proactive and positive team player. Able to maintain high performance during times of ambiguity and change in the work environment
  • Experience in financial, budget, cost management/analysis, accounting, and/or financial planning skills are desirable
  • Has knowledge of Intellectual Property issues, Publication issues, Indemnification issues and other standard issues of site contracts within the clinical research area
  • Must be willing to work in a fast-paced environment with time-sensitive material
  • Demonstrated ability to work effectively at all levels of an organization
  • Travel: 10%
  • Supervisory Responsibilities: Yes
  • Computer Skills: Microsoft Office apps, CTMS, Contract Lifecycle Management System, Veeva, Jira, Sharepoint etc.
Responsibilities
  • Functional line management of the regional based Clinical Contracts team including Contract Managers and Contract Associates or equivalent and delivers individual and group feedback to support ongoing development
  • The Regional Site Contracts Lead may have authority through a POA to sign Investigator Contracts as authorized by BeOne Medicines Legal and Tax
  • Responsible for ensuring that the negotiation process is maintained and improved to meet the financial and operational needs of the BeOne Medicines
  • Responsible for ensuring the negotiation of Clinical Site budgets is within Fair Market value and internal approval guidelines
  • Partner with Clinical Operations teams, and CBO colleagues to improve overall Clinical Site Contract and budget metrics and implement processes
  • Ensure standards are applied to the Clinical Site Contract and budget processes across project portfolios and support continuous improvement activities while developing TA aligned strategies
  • Serve as a regional escalation point for Clinical Site Contracts and provide regional oversight at the Program level
  • Leverage leading industry tools and data sources to provide budget and contract feedback aligned with BeOne Medicines parameters and fair market value guidance
  • Recognize and improve potential delays providing solutions to resolve and escalate nonperformance
  • Provide oversight and guidance for clinical site contract negotiations, identify any potential risks, and be accountable for the overall contracting timelines/lifecycle in various regions
  • Perform Regional level oversight of Clinical Site Contracts to ensure contracts in the region are completed per company standards/timelines. Implement mitigation plans as necessary in the assigned region
  • Development and implementation of new policies and procedures based on identified needs
  • Other tasks and responsibilities as requested by departmental and company leadership
Desired Qualifications
  • Experience in financial, budget, cost management/analysis, accounting, and/or financial planning skills are desirable

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE